Literature DB >> 14691125

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

David G Pfister1, David H Johnson, Christopher G Azzoli, William Sause, Thomas J Smith, Sherman Baker, Jemi Olak, Diane Stover, John R Strawn, Andrew T Turrisi, Mark R Somerfield.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 14691125     DOI： 10.1200/JCO.2004.09.053

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  277 in total

1.  Down-regulation of ALKBH2 increases cisplatin sensitivity in H1299 lung cancer cells.

Authors:  Shuang-shuang Wu; Wei Xu; Shan Liu; Bo Chen; Xue-li Wang; Yan Wang; Shi-feng Liu; Jian-qing Wu
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150

2.  Current status of postoperative follow-up for lung cancer in Japan: questionnaire survey by the Setouchi Lung Cancer Study Group-A0901.

Authors:  Shigeki Sawada; Hiroshi Suehisa; Motohiro Yamashita; Masao Nakata; Norihito Okumura; Kazunori Okabe; Hiroshige Nakamura; Hirohito Tada; Shinichi Toyooka; Hiroshi Date
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-02-12

3.  Chemotherapy: advanced NSCLC--should we use doublets in elderly patients?

Authors:  Robert Pirker
Journal:  Nat Rev Clin Oncol       Date:  2011-09-27       Impact factor: 66.675

4.  The importance of a satisfactory biopsy for the diagnosis of lung cancer in the era of personalized treatment.

Authors:  L M Ofiara; A Navasakulpong; N Ezer; A V Gonzalez
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

5.  ASCO Clinical Practice Guidelines: Past, Present and Future.

Authors:  Gary H Lyman
Journal:  J Oncol Pract       Date:  2008-09       Impact factor: 3.840

6.  American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Authors:  Christopher G Azzoli; Giuseppe Giaccone; Sarah Temin
Journal:  J Oncol Pract       Date:  2010-01       Impact factor: 3.840

7.  High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.

Authors:  Maria Ines Nunez; Carmen Behrens; Denise M Woods; Heather Lin; Milind Suraokar; Humam Kadara; Wayne Hofstetter; Neda Kalhor; J Jack Lee; Wilbur Franklin; David J Stewart; Ignacio I Wistuba
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

8.  Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599.

Authors:  Julie R Brahmer; Suzanne E Dahlberg; Robert J Gray; Joan H Schiller; Michael C Perry; Alan Sandler; David H Johnson
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

9.  Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer.

Authors:  Elisabetta Campagnoli; Isabella Garassino; Armando Santoro; Fabio De Vincenzo; Paolo Andrea Zucali; Giovanni Luca Ceresoli; Fabio Romano Lutman; Marco Alloisio; Hector Josè Soto Parra; Raffaele Cavina
Journal:  Invest New Drugs       Date:  2007-06-19       Impact factor: 3.850

Review 10.  Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer.

Authors:  James E Frampton; Stephanie E Easthope
Journal:  Drugs       Date:  2004       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.